vaccine nanoparticles9 Sep 2021 17:01
DMTR is also doing this though but we are woefully undervalued
AI-driven pharmatech
Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drug candidates are created.
The UK company’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
The company has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of the design. The company has offices in Oxford, Vienna, Dundee, Miami, and Osaka.
“The ongoing COVID-19 pandemic underscores the urgency to develop safe and effective broad-spectrum drugs to expand our armoury against viruses and their variants. We need to fight today’s pandemic but also ensure we are prepared with new drugs to combat viruses with future pandemic potential. We are honoured to work alongside the Bill & Melinda Gates Foundation to advance this mission by ensuring accessibility and affordability of these therapeutics globally,” commented Andrew Hopkins, Chief Executive Officer of Exscientia. “We believe that our AI-driven platform can accelerate the creation of better, more effective therapeutics that can address some of the world’s most critical and emerging health risks.”
“Small molecule therapeutics could provide a superior approach to guard global health,” said Denise Barrault, Director of Portfolio Management at Exscientia. “Certain targets are prevalent across families of viruses, meaning that potent therapeutics could be broadly effective across multiple virus families. Further, this collaboration will focus on evaluating protein targets that are evolutionarily conserved and are less likely to develop resistance.”
Sign In
Follow the stocks
